Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 229-238

  Yang, Chi Chen ^a,b   Hsieh, Yi Chen ^a   Lee, Shiow Ju ^a   Wu, Szu Huei ^a   Liao, Ching Len ^b   Tsao, Chang Huei ^c   Chao, Yu Sheng ^a   Chern, Jyh Haur ^a   Wu, Chung Pu ^d   Yueh, Andrew ^a,b  

^a National Health Research Institutes NHRI   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BP 2109; BP 2444; BP 5700; N,N' [(9 OXO 9H FLUORENE 2,7 DIYL)BIS(OXYETHANE 2,1 DIYL)]BIS(N,N DIETHYLDECAN 1 AMINIUM); NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VIRUS RNA;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DENGUE VIRUS; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; ENZYME INHIBITION; GENE CONSTRUCT; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HYDROPHILICITY; IC 50; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REPLICON; REPORTER GENE; RNA SYNTHESIS; SEQUENCE ANALYSIS; SEROTYPE; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CRICETINAE; DENGUE VIRUS; HIGH-THROUGHPUT SCREENING ASSAYS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650636283     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00855-10     Document Type: Article

References (51)

1. Arakaki, T. L., N. X. Fang, D. P. Fairlie, P. R. Young, and J. L. Martin. 2002. Catalytically active Dengue virus NS3 protease forms aggregates that are separable by size exclusion chromatography. Protein Expr. Purif. 25:241-247.
2. Bazan, J. F., and R. J. Fletterick. 1989. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 171:637-639.
3. Beran, R. K., and A. M. Pyle. 2008. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J. Biol. Chem. 283:29929-29937.
4. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
5. Burke, D. 2000. Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual. Cold Spring Harbor Laboratory Press, Plainview, NY.
6. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
7. Chanprapaph, S., P. Saparpakorn, C. Sangma, P. Niyomrattanakit, S. Hannongbua, C. Angsuthanasombat, and G. Katzenmeier. 2005. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem. Biophys. Res. Commun. 330:1237-1246.
8. Chen, L. K., Y. L. Lin, C. L. Liao, C. G. Lin, Y. L. Huang, C. T. Yeh, S. C. Lai, J. T. Jan, and C. Chin. 1996. Generation and characterization of organtropism mutants of Japanese encephalitis virus in vivo and in vitro. Virology 223:79-88.
9. Deas, T. S., I. Binduga-Gajewska, M. Tilgner, P. Ren, D. A. Stein, H. M. Moulton, P. L. Iversen, E. B. Kauffman, L. D. Kramer, and P. Y. Shi. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79:4599-4609.
10. Erbel, P., N. Schiering, A. D'Arcy, M. Renatus, M. Kroemer, S. P. Lim, Z. Yin, T. H. Keller, S. G. Vasudevan, and U. Hommel. 2006. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 13:372-373.
11. Falgout, B., M. Pethel, Y. M. Zhang, and C. J. Lai. 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65:2467-2475.
12. Ganesh, V. K., N. Muller, K. Judge, C. H. Luan, R. Padmanabhan, and K. H. Murthy. 2005. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg. Med. Chem. 13:257-264.
13. Gorbalenya, A. E., A. P. Donchenko, E. V. Koonin, and V. M. Blinov. 1989. N-terminal domains of putative helicases of flavi- and pestiviruses may be serine proteases. Nucleic Acids Res. 17:3889-3897.
14. Gubler, D., G. Kuno, and L. Markoff. 2007. Flaviviruses, p. 1153-1253. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 5th ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA.
15. Gubler, D. J. 1989. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig lecture. Am. J. Trop. Med. Hyg. 40:571-578.
16. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
17. Guzman, M. G., and G. Kouri. 2004. Dengue diagnosis, advances and challenges. Int. J. Infect. Dis. 8:69-80.
18. Guzman, M. G., and G. Kouri. 2002. Dengue: an update. Lancet Infect. Dis. 2:33-42.
19. Halstead, S. B. 1980. Dengue haemorrhagic fever-a public health problem and a field for research. Bull. World Health Organ. 58:1-21.
20. Houng, H. H., D. Hritz, and N. Kanesa-Thasan. 2000. Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3′-noncoding sequence. J. Virol. Methods 86:1-11.
21. Johnston, P. A., J. Phillips, T. Y. Shun, S. Shinde, J. S. Lazo, D. M. Huryn, M. C. Myers, B. I. Ratnikov, J. W. Smith, Y. Su, R. Dahl, N. D. Cosford, S. A. Shiryaev, and A. Y. Strongin. 2007. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev. Technol. 5:737-750.
22. Lai, C. Y., H. P. Hu, C. C. King, and W. K. Wang. 2008. Incorporation of dengue virus replicon into virus-like particles by a cell line stably expressing precursor membrane and envelope proteins of dengue virus type 2. J. Biomed Sci. 15:15-27.
23. Lescar, J., D. Luo, T. Xu, A. Sampath, S. P. Lim, B. Canard, and S. G. Vasudevan. 2008. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res. 80:94-101.
24. Leung, D., K. Schroder, H. White, N. X. Fang, M. J. Stoermer, G. Abbenante, J. L. Martin, P. R. Young, and D. P. Fairlie. 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem. 276:45762-45771.
25. Leyssen, P., E. De Clercq, and J. Neyts. 2008. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 78:9-25.
26. Lin, Y. L., C. L. Liao, L. K. Chen, C. T. Yeh, C. I. Liu, S. H. Ma, Y. Y. Huang, Y. L. Huang, C. L. Kao, and C. C. King. 1998. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72:9729-9737.
27. Lin, Y. L., C. C. Liu, H. Y. Lei, T. M. Yeh, Y. S. Lin, R. M. Chen, and H. S. Liu. 2000. Infection of five human liver cell lines by dengue-2 virus. J. Med. Virol. 60:425-431.
28. Luo, D., T. Xu, C. Hunke, G. Gruber, S. G. Vasudevan, and J. Lescar. 2008. Crystal structure of the NS3 protease-helicase from dengue virus. J. Virol. 82:173-183.
29. Melino, S., S. Fucito, A. Campagna, F. Wrubl, A. Gamarnik, D. O. Cicero, and M. Paci. 2006. The active essential CFNS3d protein complex. FEBS J. 273:3650-3662.
30. Menendez-Arias, L. 2010. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 85:210-231.
31. Miroux, B., and J. E. Walker. 1996. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 260:289-298.
32. Monath, T. P. 2008. Treatment of yellow fever. Antiviral Res. 78:116-124.
33. Mueller, N. H., N. Pattabiraman, C. Ansarah-Sobrinho, P. Viswanathan, T. C. Pierson, and R. Padmanabhan. 2008. Identification and biochemical characterization of small-molecule inhibitors of West Nile virus serine protease by a high-throughput screen. Antimicrob. Agents Chemother. 52:3385-3393.
34. Ng, C. Y., F. Gu, W. Y. Phong, Y. L. Chen, S. P. Lim, A. Davidson, and S. G. Vasudevan. 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res. 76:222-231.
35. Niyomrattanakit, P., P. Winoyanuwattikun, S. Chanprapaph, C. Angsuthanasombat, S. Panyim, and G. Katzenmeier. 2004. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. J. Virol. 78:13708-13716.
36. Noble, C. G., Y. L. Chen, H. Dong, F. Gu, S. P. Lim, W. Schul, Q. Y. Wang, and P. Y. Shi. 2010. Strategies for development of dengue virus inhibitors. Antiviral Res. 85:450-462.
37. Pinheiro, F. P. 1989. Dengue in the Americas. 1980-1987. Epidemiol. Bull. 10:1-8.
38. Pinheiro, F. P., and S. J. Corber. 1997. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat. Q 50:161-169.
39. Puig-Basagoiti, F., M. Tilgner, B. M. Forshey, S. M. Philpott, N. G. Espina, D. E. Wentworth, S. J. Goebel, P. S. Masters, B. Falgout, P. Ren, D. M. Ferguson, and P. Y. Shi. 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50:1320-1329.
40. Rice, C. M., E. M. Lenches, S. R. Eddy, S. J. Shin, R. L. Sheets, and J. H. Strauss. 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229:726-733.
41. Sampath, A., and R. Padmanabhan. 2009. Molecular targets for flavivirus drug discovery. Antiviral Res. 81:6-15.
42. Sikorski, R. S., and P. Hieter. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27.
43. Soriano, V., A. Madejon, E. Vispo, P. Labarga, J. Garcia-Samaniego, L. Martin-Carbonero, J. Sheldon, M. Bottecchia, P. Tuma, and P. Barreiro. 2008. Emerging drugs for hepatitis C. Expert Opin. Emerg. Drugs 13:1-19.
44. Valle, R. P., and B. Falgout. 1998. Mutagenesis of the NS3 protease of dengue virus type 2. J. Virol. 72:624-632.
45. Wichapong, K., S. Pianwanit, W. Sippl, and S. Kokpol. 2010. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction. J. Mol. Recognit. 23:283-300.
46. Wu, C. F., S. H. Wang, C. M. Sun, S. T. Hu, and W. J. Syu. 2003. Activation of dengue protease autocleavage at the NS2B-NS3 junction by recombinant NS3 and GST-NS2B fusion proteins. J. Virol. Methods 114:45-54.
47. Wu, S. F., C. J. Lee, C. L. Liao, R. A. Dwek, N. Zitzmann, and Y. L. Lin. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76:3596-3604.
48. Yin, Z., S. J. Patel, W. L. Wang, W. L. Chan, K. R. Ranga Rao, G. Wang, X. Ngew, V. Patel, D. Beer, J. E. Knox, N. L. Ma, C. Ehrhardt, S. P. Lim, S. G. Vasudevan, and T. H. Keller. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 16:40-43. (Pubitemid 41625637)
49. Yin, Z., S. J. Patel, W. L. Wang, G. Wang, W. L. Chan, K. R. Rao, J. Alam, D. A. Jeyaraj, X. Ngew, V. Patel, D. Beer, S. P. Lim, S. G. Vasudevan, and T. H. Keller. 2006. Peptide inhibitors of Dengue virus NS3 protease. Part 1: warhead. Bioorg. Med. Chem. Lett. 16:36-39.
50. Yusof, R., S. Clum, M. Wetzel, H. M. Murthy, and R. Padmanabhan. 2000. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J. Biol. Chem. 275:9963-9969.
51. Zou, G., F. Puig-Basagoiti, B. Zhang, M. Qing, L. Chen, K. W. Pankiewicz, K. Felczak, Z. Yuan, and P. Y. Shi. 2009. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384:242-252.